The Centers for Disease Control and Prevention awarded Boston Medical Center Corporation an indefinite delivery contract with a potential value of $86 million to provide Clinical Immunization Safety Assessment services. The base IDIQ establishes terms and conditions for future delivery orders related to immunization safety assessments to support the Department of Health and Human Services.
Two initial cost-no-fee delivery orders totaling $1.9 million have been issued against the IDIQ. The first, valued at $1.1 million, tasks BMC with providing CISA services from September 2023 through September 2028 in Boston, Massachusetts. The second, valued at $910,040, requires CISA services be conducted from September 2023 to September 2026 to support HHS immunization program activities. Both delivery orders were awarded on September 28, 2023 by the CDC in Pittsburgh and will be performed in Boston.
No set-asides or subcontracting arrangements were outlined. The contract aims to leverage BMC's expertise to evaluate immunization safety and inform HHS programs, consistent with the CDC's mission to protect public health through immunization and detection of adverse events. Future orders against the IDIQ will further these efforts over the five-year base period of performance.
Generated 1/4/24, 9:25 PM